FibroGen (NASDAQ: FGEN) reported Q2 EPS of ($1.45), $1.00 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $24.4 million versus the consensus estimate of $71.38 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.